From Here to Maternity

You’re determined to conceive.
We’re determined to help. 

If you’re having trouble becoming pregnant, you’ve come to the right place.
At Ferring Pharmaceuticals, we understand your goal to bring a baby into
the world, and we’re here to help you reach that goal. And we’re ready to
be there every step of the way—from helping you learn about various
conditions that may affect you to finding effective treatment options so
you can fulfill your dream of parenthood.

While you’re visiting this site, you’ll see journal entries on many pages, highlighting the feelings of women just like you—trying to conceive.
Each time you visit, you’ll know you’re not alone on your journey from
here to maternity. And at Ferring, we’re doing all we can to get you there.

Ferring Pharmaceuticals
Helping you achieve what your heart dreams.

CONTACT   INTERNATIONAL   U.S.A.   |   TERMS & CONDITIONS
© 2007 Ferring Pharmaceuticals Inc.

MENOPUR® administered subcutaneously is indicated for the development of multiple follicles and pregnancy in the ovulatory patients participating in an ART program. BRAVELLE® administered SC in conjunction with hCG is indicated for multiple follicular development (controlled ovarian stimulation) during ART cycles in patients who have previously received pituitary suppression. BRAVELLE® administered SC or IM, in conjunction with hCG, is indicated for ovulation induction in patients who have previously received pituitary suppression.

ENDOMETRIN® administered as a progesterone vaginal insert is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment for infertile women.

Important Safety Information

Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe BRAVELLE® and MENOPUR®. BRAVELLE® and MENOPUR®, like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (overall incidence of 6.0% for BRAVELLE® and 3.8% for MENOPUR®), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. BRAVELLE® and MENOPUR® are contraindicated in women who have a high FSH level indicating primary ovarian failure; uncontrolled thyroid and adrenal dysfunction; an organic intracranial lesion such as a pituitary tumor; abnormal uterine bleeding of undetermined origin; ovarian cysts or enlargement not due to polycystic ovary syndrome; prior hypersensitivity to respectively, urofollitropins, purified, and menotropins or MENOPUR®. BRAVELLE® is contraindicated for the presence of any cause of infertility other than anovulation. MENOPUR® is contraindicated for sex hormone dependent tumors of the reproductive tract and accessory organs. BRAVELLE® and MENOPUR® are contraindicated in women who are pregnant. BRAVELLE® may cause fetal harm when administered to a pregnant woman. There are limited human data on the effects of BRAVELLE® and menotropins when administered during pregnancy.

Only physicians thoroughly familiar with infertility treatment should prescribe ENDOMETRIN®. In clinical trials (n=808), adverse reactions that occurred at a rate greater than or equal to 2% included: uterine spasm (3% to 4%) and vaginal bleeding (3%). Vaginal irritation, itching, burning or discomfort, urticaria, and peripheral edema were reported at an incidence of less than 2%. ENDOMETRIN® is expected to have adverse reactions similar to other drugs containing progesterone (breast tenderness, bloating, mood swings, irritability, and drowsiness). ENDOMETRIN® is contraindicated in women who have or have had previous allergic reactions to progesterone or any of the ingredients in ENDOMETRIN®; a known missed abortion or ectopic pregnancy; liver disease; known or suspected breast cancer; active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.

Click here to see Full Prescribing Information for MENOPUR®, BRAVELLE®, and ENDOMETRIN®.

Sharps Disposal Information